Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Featured
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.
Latest
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide powder: what the label says
Forum questions about reconstituting tirzepatide powder reveal a key fact: FDA-approved tirzepatide is supplied ready-to-inject, not as a lyophilized powder.
Tirzepatide vs care in early T2D at 2 years
A 2-year trial in Annals of Internal Medicine finds tirzepatide reduces HbA1c and weight more than intensified conventional care in early T2D.
Tirzepatide vs semaglutide: meta-analysis
A 2026 meta-analysis in Clinical Obesity pooled head-to-head and indirect trial data comparing tirzepatide and semaglutide for weight loss.
Is CJC-1295/ipamorelin flushing normal?
Facial flushing after CJC-1295 and ipamorelin injections is a known, documented reaction pattern for this peptide class, not an unusual one.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
What is KLOW? The peptide blend, explained
KLOW mixes BPC-157, TB-500, GHK-Cu, and KPV. Here is what the evidence for each ingredient shows, and why none of it answers a fracture-healing question.
PT-141 for low libido on GLP-1 drugs
Reduced libido is a reported side effect on GLP-1 drugs. Here is what the evidence shows for PT-141 (bremelanotide) and kisspeptin as options for women.
Retatrutide and DKA in type 1 diabetes
A Cureus 2026 case report: a type 1 diabetes patient self-injected online-sourced retatrutide and developed impending DKA alongside a Shigella infection.
A nasal spray for semaglutide? Not yet
Sydney researchers built a needle-free nasal nanocarrier for semaglutide and tested it in cells and animals, not yet in people.
Categories
Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Comparison
Peptide-vs-peptide, country-vs-country, label-vs-grey-market. Methodology disclosed, conclusions tied to primary sources.
Vendor accountability
Counterfeit warnings, supply-chain incidents, Certificates of Analysis read in detail. We do not sell peptides and we do not promote vendors; we hold them to the same evidence bar as everyone else.
Methodology
How we score evidence depth, source recency and safety clarity. Behind-the-scenes editorial decisions. The reasoning, not just the result.
Country deep-dive
Single-country regulatory or market reports. How peptides actually move through Danish customs; what the BfArM said about a specific schedule shift; the German press response to a Mounjaro shortage.